Comparative Pharmacology
Head-to-head clinical analysis: BUMEX versus TORSEMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUMEX versus TORSEMIDE.
BUMEX vs TORSEMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bumetanide inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Torsemide inhibits the Na+/K+/2Cl- cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption, leading to increased urine output and decreased extracellular fluid volume.
0.5-2 mg orally once daily; if inadequate response, may increase to 2-4 mg once daily or twice daily. Maximum 10 mg/day. IV: 0.5-1 mg IV over 1-2 minutes; may repeat every 2-3 hours up to 10 mg/day.
Oral or intravenous: 5-20 mg once daily; may titrate up to 40 mg daily. Usual maintenance: 5-10 mg daily.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in normal renal function; prolonged to 2.5–4 hours in severe renal impairment (CrCl <20 mL/min).
Terminal elimination half-life is 3-4 hours in healthy adults; prolonged to 4-8 hours in cirrhosis and with advanced age. In renal failure (CrCl <30 mL/min), half-life may exceed 8 hours.
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; total renal elimination accounts for ~85% of clearance.
Approximately 80% renal (20% unchanged, 60% as metabolites, mainly glucuronide conjugate), 20% biliary/fecal. In renal impairment, clearance is reduced and half-life prolonged.
Category C
Category A/B
Loop Diuretic
Loop Diuretic